FINWIRES · TerminalLIVE
FINWIRES

Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34

By

ResMed (ASX:RMD) has an average rating of overweight and mean price target of AU$38.72, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles

Research

Roth Capital Upgrades Comstock Resources to Neutral From Sell, $13 Price Target

Comstock Resources (CRK) has an average rating of hold and mean price target of $20.12, according to analysts polled by FactSet.Price: $12.94, Change: $-0.75, Percent Change: -5.48%

$CRK
Research

BofA Downgrades Weyerhaeuser to Neutral From Buy, Price Target is $26

Weyerhaeuser (WY) has an average rating of overweight and mean price target of $31.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $23.53, Change: $+1.03, Percent Change: +4.58%

$WY
Research

Raymond James Upgrades Weyerhaeuser to Strong Buy From Outperform, Price Target is $30

Weyerhaeuser (WY) has an average rating of overweight and mean price target of $31.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $23.53, Change: $+1.03, Percent Change: +4.58%

$WY